# US 2024/0002854 A1 · Albumin Production and Cell Proliferation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002854 A1
- Document ID: US20240002854A1
- Status: Published application
- Kind: A1
- Application number: 18/316,556
- Filed: 2023-05-12
- Published: 2024-01-04
- Earliest claimed: 2011-06-21
- Assignees: Mina Therapeutics Limited
- Applicants: MiNA Therapeutics Limited
- Inventors: Pål Sætrom
- Web page: https://patentgrep.com/patent/US20240002854A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 35/00: Antineoplastic agents
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2320/30: Special therapeutic applications
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides short activating RNA molecules which up-regulate albumin production. The present invention also provides methods of up-regulating albumin production, such methods involving the use of short activating RNA molecules capable of increasing the expression of albumin. The present invention also provides the use of the short activating RNA molecules in therapy, such as treating or preventing a hyperproliferative disorder and/or a disorder characterised by hypoalbuminemia.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A synthetic short activating RNA (saRNA) which up-regulates the expression of a target gene,
wherein the target gene is CEBPA, albumin or HNF4a,
wherein the saRNA comprises an antisense stand that is 13 nucleotides to 30 nucleotides in length, and
wherein the antisense stand comprises a sequence that overlaps the promoter region of the target gene and a number of unpaired nucleotides at the 3′ end forming 3′ overhangs.

### Claim 23 (depends on 22)

The saRNA of claim 22, wherein the saRNA is double stranded and comprises an anti-sense strand having a sequence of SEQ ID NOs: 14, 16, 18, 20, 22, 24, 6, 8, 10, 12, 26, 28, 30, 32, 34 or 36.

### Claim 24 (depends on 23)

The saRNA of claim 23, wherein the saRNA comprises a sense strand having a sequence of SEQ ID NOs: 13, 15, 17, 19, 21, 23, 5, 7, 9, 11, 25, 27, 29, 31, 33 or 35.

### Claim 25 (depends on 24)

The saRNA of claim 24, wherein each strand of the saRNA comprises a 3′ overhang of 1-5 nucleotides.

### Claim 26 (depends on 25)

The saRNA of claim 25, wherein said 3′ overhang is UU or UUU.

### Claim 27 (depends on 22)

A method of up-regulating the expression of a target gene in a cell, wherein the target gene is CEBPA, albumin or HNF4a, comprising transfecting said cell with the saRNA of claim 22.

### Claim 28 (depends on 27)

The method of claim 27, wherein the cell is a cancer cell.

### Claim 29 (depends on 27)

The method of claim 27, wherein the cell is a liver cell.

### Claim 30 (depends on 27)

The method of claim 27, wherein the cell is a liver cancer cell.

### Claim 31 (depends on 22)

A method of treating a hyperproliferative disorder and/or a disorder characterized by hypoalbuminemia in a subject, comprising administering the saRNA of claim 22 to the subject.

### Claim 32 (depends on 31)

The method of claim 31, wherein the subject has liver cancer.

### Claim 33 (depends on 22)

A method of treating liver cirrhosis in a subject, comprising administering the saRNA of claim 22 to the subject.
